![Submit your clinical case about site-agnostic treatment/precision oncology in Lung Cancer – European School of Oncology](https://oncodaily.com/pub/uploads/2024/09/esoooo-1280x960.jpg)
Submit your clinical case about site-agnostic treatment/precision oncology in Lung Cancer – European School of Oncology
European School of Oncology (ESO) shared a post on LinkedIn:
“Submit your clinical case and discuss it live online with top level experts!
- Topic: Site-agnostic treatment/precision oncology.
- Focus: Lung Cancer
- Experts: Prof Alfredo Addeo and Prof Umberto Malapelle
The Experts will select one presentation for each of the following subtopics:
- EGFR Mutation in Metastatic Lung Cancer
- Advanced ALK-positive Lung Cancer
- Early-Stage Ret-Fusion NSLCL
Deadline: 4 October 2024
Learn more.”
Source: European School of Oncology/LinkedIn
Alfredo Addeo is the Head of Oncology at the University Hospital of Geneva (HUG), Switzerland. His research focuses on circulating tumor DNA, liquid biopsies, and biomarkers in thoracic malignancies. He is an active member of ESMO, ETOP, and IASLC.
Umberto Malapelle is an Associate Professor in the School of Medicine at the University of Naples Federico II. He is the Chair of the Predictive Molecular Pathology Laboratory in the Department of Public Health at the same university.
He also serves as the Scientific Secretary of the International Society of Liquid Biopsy and is the Editor-in-Chief of The Journal of Liquid Biopsy. His research focuses on genomic biomarkers for predicting outcomes in lung cancer, colorectal cancer, melanoma, and gastrointestinal stromal tumors.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023